(Q52569827)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

acute myeloid leukemia

1 reference

core binding factor acute myeloid leukemia

inferred from title

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Bruno Quesnel

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Claude Preudhomme

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

N Boissel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

H Leroy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

B Brethon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

N Philippe

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

S de Botton

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Auvrignon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

E Raffoux

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

T Leblanc

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

X Thomas

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Baruchel

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

G Leverger

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

H Dombret

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Acute Leukemia French Association (ALFA)

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

965-970

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404188

19 January 2020

exact match

0 references

cites work

Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Genetics of myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Flt3 mutations and leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404188

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404188

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16598313%20AND%20SRC:MED&resulttype=core&format=json

release_usxd2z3w4reljchxhcxswonu6q

19 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/usxd2z3w4reljchxhcxswonu6q

24 November 2022

mapped directly with Wikidata item

1 reference